General Information of Drug Combination (ID: DCOUT2D)

Drug Combination Name
Ribavirin Interferon Alfa-2b
Indication
Disease Entry Status REF
Middle East Respiratory Syndrome (MERS) Investigative [1]
Component Drugs Ribavirin   DMEYLH9 Interferon Alfa-2b   DMWCQP4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ribavirin
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Approved [2]
Respiratory syncytial virus infection 1C80 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [1]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [5]
Ribavirin Interacts with 5 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HUMAN inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) TT3GRLK IMDH1_HUMAN Inhibitor [4]
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) TTL7C8Q IMDH1_HUMAN Inhibitor [8]
HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) TTTU6X1 IMDH2_HUMAN Inhibitor [4]
MERS-CoV RNA-directed RNA polymerase (RdRp) TTOA6YT R1AB_CVEMC (4378-5310) Inhibitor [5]
SARS-CoV RNA-directed RNA polymerase (RdRp) TTKXI53 R1AB_CVHSA (4370-5301) Inhibitor [5]
------------------------------------------------------------------------------------
Ribavirin Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [9]
Concentrative nucleoside transporter 2 (SLC28A2) DT82KPY S28A2_HUMAN Substrate [10]
Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3) DT4YL5R S28A3_HUMAN Substrate [11]
Equilibrative nucleoside transporter 1 (SLC29A1) DTXD1TQ S29A1_HUMAN Substrate [12]
------------------------------------------------------------------------------------
Ribavirin Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Purine nucleoside phosphorylase (PNP) DE2WSAL PNPH_HUMAN Metabolism [13]
Cytosolic 5'-nucleotidase II (NT5C2) DE1DOKJ 5NTC_HUMAN Metabolism [14]
------------------------------------------------------------------------------------
Ribavirin Interacts with 43 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Protein arginine N-methyltransferase 5 (PRMT5) OTF6IGJS ANM5_HUMAN Decreases Expression [15]
Protein arginine N-methyltransferase 3 (PRMT3) OTH2KILE ANM3_HUMAN Decreases Expression [7]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [16]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [17]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Decreases Expression [18]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [19]
Erythropoietin (EPO) OTZ90CN4 EPO_HUMAN Increases Expression [20]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [21]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Decreases Expression [17]
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Decreases Expression [17]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [22]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Decreases Expression [7]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Decreases Expression [15]
Myosin-6 (MYH6) OT3YNCH1 MYH6_HUMAN Decreases Expression [21]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [21]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [15]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Decreases Expression [17]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [16]
G1/S-specific cyclin-E1 (CCNE1) OTLD7UID CCNE1_HUMAN Decreases Expression [15]
Sodium-dependent serotonin transporter (SLC6A4) OT6FGDLW SC6A4_HUMAN Increases Expression [23]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [16]
Alpha-actinin-2 (ACTN2) OT9FOLD7 ACTN2_HUMAN Decreases Expression [21]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Phosphorylation [16]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [24]
Transcription factor GATA-4 (GATA4) OTQHWAZG GATA4_HUMAN Decreases Expression [21]
Troponin T, cardiac muscle (TNNT2) OT80NN7R TNNT2_HUMAN Decreases Expression [21]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Decreases Response To Substance [25]
Protein arginine N-methyltransferase 2 (PRMT2) OT63JZCI ANM2_HUMAN Decreases Expression [7]
Interleukin-2 (IL2) OTGI4NSA IL2_HUMAN Increases Expression [17]
Insulin gene enhancer protein ISL-1 (ISL1) OTVNVKAX ISL1_HUMAN Decreases Expression [21]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) OTHBQVD5 4EBP1_HUMAN Decreases Phosphorylation [16]
Histone-arginine methyltransferase CARM1 (CARM1) OT0IPRVR CARM1_HUMAN Decreases Expression [7]
Protein arginine N-methyltransferase 6 (PRMT6) OT5V3XIN ANM6_HUMAN Affects Expression [7]
Protein arginine N-methyltransferase 1 (PRMT1) OTN8GTXW ANM1_HUMAN Affects Expression [7]
Protein arginine N-methyltransferase 8 (PRMT8) OT3MRK62 ANM8_HUMAN Decreases Expression [7]
Protein arginine N-methyltransferase 7 (PRMT7) OTE73PO1 ANM7_HUMAN Decreases Expression [15]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Increases ADR [26]
Hepatocyte growth factor (HGF) OTGHUA23 HGF_HUMAN Increases ADR [26]
Equilibrative nucleoside transporter 3 (SLC29A3) OTGLX8XU S29A3_HUMAN Affects Transport [27]
Haptoglobin (HP) OTGUGAF9 HPT_HUMAN Increases ADR [26]
Equilibrative nucleoside transporter 1 (SLC29A1) OTLOOZZS S29A1_HUMAN Increases Uptake [28]
Interferon lambda-3 (IFNL3) OTPIMGAU IFNL3_HUMAN Decreases Response [29]
Inosine triphosphate pyrophosphatase (ITPA) OTQ47WVR ITPA_HUMAN Increases Response To Substance [30]
------------------------------------------------------------------------------------
⏷ Show the Full List of 43 DOT(s)
Indication(s) of Interferon Alfa-2b
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [2]
Interferon Alfa-2b Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Interferon-alpha 2 (IFNA2) TTSIUJ9 IFNA2_HUMAN Modulator [32]
------------------------------------------------------------------------------------
Interferon Alfa-2b Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Increases Expression [31]
Interferon-induced, double-stranded RNA-activated protein kinase (EIF2AK2) OT8DXMS3 E2AK2_HUMAN Increases Expression [31]
Tyrosine-protein kinase JAK1 (JAK1) OT0X3D17 JAK1_HUMAN Increases Expression [31]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Increases Phosphorylation [31]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Increases Expression [31]
Signal transducer and activator of transcription 2 (STAT2) OTO9G2RZ STAT2_HUMAN Increases Phosphorylation [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Ribavirin FDA Label
4 Proteomics of SARS-CoV-2-infected Host Cells Reveals Therapy Targets. Nature. 2020 May 14. doi: 10.1038/s41586-020-2332-7.
5 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
6 Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia. Clin Pharmacol Ther. 2005 Oct;78(4):422-32. doi: 10.1016/j.clpt.2005.07.002.
7 Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol. 2022 Jan 15;435:115829. doi: 10.1016/j.taap.2021.115829. Epub 2021 Dec 14.
8 Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13.
9 Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. J Pharm Sci. 2006 Jun;95(6):1318-25.
10 Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. Pharmacogenet Genomics. 2007 Sep;17(9):783-6.
11 Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Biophys Chem. 2010 Mar;147(1-2):59-65.
12 Effects of dipyridamole coadministration on the pharmacokinetics of ribavirin in healthy volunteers. Drug Metab Pharmacokinet. 2013;28(5):406-10.
13 Functional analysis of purine nucleoside phosphorylase as a key enzyme in ribavirin metabolism. Drug Metab Pharmacokinet. 2014;29(2):211-4.
14 Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother. 2005 Jun;49(6):2164-71.
15 Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation. Toxicol Appl Pharmacol. 2021 Mar 15;415:115450. doi: 10.1016/j.taap.2021.115450. Epub 2021 Feb 9.
16 Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
17 Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999 Mar;30(3):376-82. doi: 10.1016/s0168-8278(99)80093-2.
18 Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res. 2007 Jul;75(1):36-42. doi: 10.1016/j.antiviral.2006.11.008. Epub 2006 Dec 13.
19 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
20 Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia. Antivir Ther. 2003 Feb;8(1):57-63.
21 Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology. 2020 Apr 15;435:152422. doi: 10.1016/j.tox.2020.152422. Epub 2020 Feb 26.
22 Correlation of sICAM-1 and sVCAM-1 level with biochemical, histological and viral findings in chronic hepatitis C after interferon-alpha + ribavirin therapy. Rom J Gastroenterol. 2003 Jun;12(2):91-5.
23 Serotonin transporter mRNA expression is decreased by lamivudine and ribavirin and increased by interferon in immune cells. Scand J Immunol. 2006 Feb;63(2):106-15. doi: 10.1111/j.1365-3083.2005.01715.x.
24 Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells. Antimicrob Agents Chemother. 2003 Jun;47(6):1912-21. doi: 10.1128/AAC.47.6.1912-1921.2003.
25 Two distinct phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells. J Biol Chem. 2003 May 16;278(20):18092-100. doi: 10.1074/jbc.M300265200. Epub 2003 Mar 13.
26 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
27 Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. doi: 10.1152/ajpgi.90672.2008. Epub 2009 Jan 22.
28 Characterization of ribavirin uptake systems in human hepatocytes. J Hepatol. 2010 Apr;52(4):486-92.
29 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon--based regimens. Clin Pharmacol Ther. 2014 Feb;95(2):141-6. doi: 10.1038/clpt.2013.203. Epub 2013 Oct 4.
30 ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010 Oct;139(4):1190-7. doi: 10.1053/j.gastro.2010.06.071. Epub 2010 Jul 14.
31 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon / by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells. Toxicol Appl Pharmacol. 2017 Dec 1;336:31-39. doi: 10.1016/j.taap.2017.10.004. Epub 2017 Oct 12.
32 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.